TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Revenue of TELA Bio, Inc. (TELA)
Revenue in 2023 (TTM): $58.45 M
According to TELA Bio, Inc.'s latest financial reports the company's current revenue (TTM) is $58.45 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of TELA Bio, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $58.45 M | $40.11 M | $-40,633,000 | $-46,664,000 | $-46,664,000 |
| 2022 | $41.42 M | $27.04 M | $-39,058,000 | $-44,296,000 | $-44,337,000 |
| 2021 | $29.46 M | $18.81 M | $-29,144,000 | $-33,276,000 | $-36,110,000 |
| 2020 | $18.21 M | $11.23 M | $-24,705,000 | $-28,794,000 | $-31,878,000 |
| 2019 | $15.45 M | $9.27 M | $-18,234,000 | $-22,425,000 | $-25,803,000 |
| 2018 | $8.27 M | $2.94 M | $-18,042,000 | $-21,092,000 | $-21,092,000 |
| 2017 | $4.25 M | $2.53 M | $-16,015,000 | $-21,334,000 | $-21,334,000 |